Merck,
known as MSD outside the United States and Canada, will pay up to $550 million
for Germany-based Rigontec, said to be a pioneer in accessing the retinoic
acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a
novel and distinct approach in cancer immunotherapy to induce both immediate
and long-term anti-tumor immunity.
Rigontec’s
lead candidate, RGT100, is currently in Phase I development evaluating
treatment in patients with various tumors. Merck, through a subsidiary, will
make an upfront cash payment of €115 million to Rigontec’s shareholders; based
on the attainment of certain clinical, development, regulatory and commercial
milestones, Merck may make additional contingent payments of up to €349 million.
“Rigontec’s
immuno-oncology approach of engaging the innate immune system to safely
eliminate cancer cells complements our strategy and our current pipeline,” said
Dr. Eric Rubin, vice president of early-stage development, clinical oncology,
Merck Research Laboratories. “We are eager to build upon Rigontec’s science as
we continue our efforts in bringing forward meaningful advances for patients
with cancer.”
For
more information about Merck's oncology clinical trials, visit www.merck.com/clinicaltrials.
0 comentários:
Postar um comentário